EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐ CD 73/anti‐ PD ‐ L 1 immunotherapy in arm A of the NSGO ‐ OV ‐ UMB1 / ENGOT ‐ OV 30 trial

Luka Tandaric iD, Annika Auranen, Katrin Kleinmanns, René DePont Christensen, Liv Cecilie Vestrheim Thomsen, Cara Ellen Wogsland, Emmet McCormack, Johanna Mäenpää, Kristine Madsen, Karen Stampe Petersson, Mansoor Raza Mirza, Line Bjørge

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.13811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Luka Tandaric und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway. Hauptthemen laut MEDLINE: Immunotherapy, Biomarkers, Tumor, Ovarian Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norges Forskningsråd, AstraZeneca United States, Helse Vest.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have demonstrated limited efficacy in overcoming immunosuppression in patients with epithelial ovarian cancer (EOC). Although certain patients experience long‐term treatment benefit, reliable biomarkers for responder pre‐selection and the distinction of dominant immunosuppressive mechanisms have yet to be identified. Here, we used a 40‐marker suspension mass cytometry panel to comprehensively phenotype peripheral blood leukocytes sampled over time from patients with relapsed EOC who underwent combination oleclumab (anti‐CD73) and durvalumab (anti‐PD‐L1) immunotherapy in the NSGO‐OV‐UMB1/ENGOT‐OV30 trial. We found that survival duration was impacted by baseline abundances of total peripheral blood mononuclear cells. Longitudinal analyses revealed a significant increase in CD14 + CD16 − myeloid cells during treatment, with significant expansion of monocytic myeloid‐derived suppressor cells occurring in patients with shorter progression‐free survival, who additionally showed a continuous decrease in central memory T‐cell abundances. All patients demonstrated significant PD‐L1 upregulation over time on most T‐cell subsets. Higher CD73 and IDO1 expression on certain leukocytes at baseline significantly positively correlated with longer progression‐free survival. Overall, our study proposes potential biomarkers for EOC immunotherapy personalization and response monitoring; however, further validation in larger studies is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyBiomarkers, TumorOvarian NeoplasmsB7-H1 AntigenNeoplasm Recurrence, LocalLeukocytesCarcinoma, Ovarian EpithelialHumansFemaleMiddle AgedAgedAntibodies, Monoclonal

Stichwörter der Autor:innen

biomarkersdurvalumabimmunotherapyliquid biopsyoleclumabovarian cancer

Substanzen

Biomarkers, TumorB7-H1 AntigenCD274 protein, humandurvalumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway.
  • Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.
  • Department of Obstetrics and Gynecology and Tays Cancer Centre, Tampere University Hospital, Finland.
  • Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU), Tampere, Finland.
  • Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark.
  • Department of Health Registry Research and Development, Norwegian Institute of Public Health, Oslo, Norway.

ORCID-Profile: Luka Tandaric

Förderung

  • Norges Forskningsråd
  • AstraZeneca United States
  • Helse Vest

Zitieren

APA

Tandaric, L., Auranen, A., Kleinmanns, K., DePont Christensen, R., Vestrheim Thomsen, L. C., Wogsland, C. E., McCormack, E., Mäenpää, J., Madsen, K., Stampe Petersson, K., Mirza, M. R., & Bjørge, L. (2025). Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐ CD 73/anti‐ PD ‐ L 1 immunotherapy in arm A of the NSGO ‐ OV ‐ UMB1 / ENGOT ‐ OV 30 trial. Molecular Oncology. https://doi.org/10.1002/1878-0261.13811

Vancouver

Tandaric L, Auranen A, Kleinmanns K, DePont Christensen R, Vestrheim Thomsen LC, Wogsland CE, et al. Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐ CD 73/anti‐ PD ‐ L 1 immunotherapy in arm A of the NSGO ‐ OV ‐ UMB1 / ENGOT ‐ OV 30 trial. Molecular Oncology. 2025. doi:10.1002/1878-0261.13811

BibTeX
@article{Tandaric2025,
  author = {Tandaric, Luka and Auranen, Annika and Kleinmanns, Katrin and DePont Christensen, René and Vestrheim Thomsen, Liv Cecilie and Wogsland, Cara Ellen and McCormack, Emmet and Mäenpää, Johanna and Madsen, Kristine and Stampe Petersson, Karen and Mirza, Mansoor Raza and Bjørge, Line},
  title = {Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐ CD 73/anti‐ PD ‐ L 1 immunotherapy in arm A of the NSGO ‐ OV ‐ UMB1 / ENGOT ‐ OV 30 trial},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.13811}
}
Kostenlos starten →